This agent, consisting of 2 (attenuated) IFNα2b molecules fused to the Fc portion of a humanized, anti-CD38 mAb, is designed to induce direct antiproliferative effects on myeloma cells and cause both direct and indirect immune cell activation [92]. The gene discussed is CD38; the disease is plasma cell myeloma.